Log In Sign up
The largest database of trusted experimental protocols
> Chemicals & Drugs > Organic Chemical > Aldosterone

Aldosterone

Aldosterone is a mineralocoricoid hormone produced by the adrenal glands that regulates sodium and potassium balance in the body.
It plays a key role in maintaining blood pressure and fluid balance.
Aldostrone's effects include increasing sodium reabsoprtion and potassium excretion in the kidneys, as well as promoting water retention.
Dysregulation of aldosterone levels can contribute to conditions like hypertension, congestive heart failure, and kidney disease.
Accurate measurement and analysis of aldosterone levels is important for diagnosing and managing these related disorders.

Most cited protocols related to «Aldosterone»

1
Autosomal Dominant Polycystic Kidney Disease Progression
The primary outcome was the percentage change in the total kidney volume over time. The first secondary outcome was the rate of change in the estimated GFR. Other secondary outcomes included rates of change in urinary aldosterone excretion, urinary albumin excretion, left-ventricular-mass index, and renal blood flow; frequency of hospitalizations for any cause and for cardiovascular causes; quality of life; frequency of pain associated with symptoms of ADPKD; and adverse effects related to the study medication. Hospitalizations were adjudicated by investigators who were unaware of the treatment-group assignments and who determined the principal diagnosis and related procedures, whether hospitalization was related to ADPKD, and whether acute kidney injury occurred during hospitalization. Acute kidney injury was defined as an elevation in the serum creatinine level of 0.3 mg per deciliter (30 μmol per liter) or more29 (link) from the time of hospital admission or from the most recent value obtained at the study site. A discharge diagnosis of acute kidney injury was accepted if no creatinine values were available.
Schrier R.W., Abebe K.Z., Perrone R.D., Torres V.E., Braun W.E., Steinman T.I., Winklhofer F.T., Brosnahan G., Czarnecki P.G., Hogan M.C., Miskulin D.C., Rahbari-Oskoui F.F., Grantham J.J., Harris P.C., Flessner M.F., Bae K.T., Moore C.G, & Chapman A.B. (2014). Blood Pressure in Early Autosomal Dominant Polycystic Kidney Disease. The New England journal of medicine, 371(24), 2255-2266.
Publication 2014
Albumins Aldosterone Cardiovascular System Creatinine Diagnosis Flow, Renal Blood Hospitalization Kidney Kidney Injury, Acute Left Ventricles Pain Patient Discharge Polycystic Kidney, Autosomal Dominant Serum Urine
2
Measurement of MBG and Ouabain Levels
For measurement of MBG and endogenous ouabain, samples of plasma and urine were extracted on SepPak C-18 cartridges (Waters, Milford, Massachusetts, USA) as described previously in detail [11 (link)]. The MBG DELFIA fluoroimmunoassays based on anti-MBG 3E9 and 4G4 mAbs were performed as previously described for rabbit anti-MBG polyclonal antibodies [11 (link)]. The assay is based on competition between immobilized antigen (MBG-glycoside-thyroglobulin) and MBG, other cross-reactants, or endogenous CTS within the sample for a limited number of binding sites on an anti-MBG mAbs. Secondary (goat antimouse) antibody labeled with non-radioactive europium was obtained from Perkin-Elmer (Waltham, Massachusetts, USA).
The endogenous ouabain assay was based on a similar principle utilizing an ouabain–ovalbumin conjugate and ouabain antiserum (anti-OU-M-2005; 1 : 20 000) obtained from rabbits immunized with a ouabain-BSA conjugate [20 (link)]. The cross-reactivity of this ouabain antibody is (%) ouabain, 100; ouabagenin, 52, digoxin, 1.8; digitoxin, 0.47; progesterone, 0.002; prednisone, 0.001; proscillaridin, 0.03; bufalin, 0.10; aldosterone, 0.04; telocinobufagin, 0.02; resibufagin, 0.15; marinobufotoxin, 0.06; cinobufagin, 0.02; and MBG, 0.036.
Fedorova O.V., Simbirtsev A.S., Kolodkin N.I., Kotov A.Y., Agalakova N.I., Kashkin V.A., Tapilskaya N.I., Bzhelyansky A., Reznik V.A., Frolova E.V., Nikitina E.R., Budny G.V., Longo D.L., Lakatta E.G, & Bagrov A.Y. (2008). Monoclonal antibody to an endogenous bufadienolide, marinobufagenin, reverses preeclampsia-induced Na/K-ATPase inhibition and lowers blood pressure in NaCl-sensitive hypertension. Journal of hypertension, 26(12), 2414-2425.
Publication 2008
Aldosterone Anti-Antibodies Antigens Binding Sites Biological Assay bufalin Cardiac Glycosides cinobufagin Cross Reactions Digitoxin Digoxin Europium Fluoroimmunoassay Goat Immune Sera Immunoglobulins marinobufotoxin Monoclonal Antibodies Oryctolagus cuniculus ouabagenin Ouabain Ovalbumin Plasma Prednisone Progesterone Proscillaridin Rabbits telocinobufagin Thyroglobulin Urine
3
Evaluating Tolvaptan for ADPKD
The composite primary outcome was the time to death, end-stage renal disease (ESRD; defined as the initiation of dialysis or preemptive transplantation), or a 50% reduction from the baseline estimated GFR (confirmed by assessment of a second sample and adjudicated by the end-points committee, whose members were unaware of the study-medication assignments). Secondary outcomes included the rates of change in urinary albumin and aldosterone excretion, the frequency of hospitalizations for any cause and for cardiovascular causes, quality of life, incidence of pain, the frequency of symptoms related to ADPKD, and adverse study-medication effects. Hospitalizations were adjudicated by the end-points committee and evaluated with respect to the principal diagnosis, whether hospitalization was related to ADPKD, and whether the criteria for acute kidney injury, as described by Schrier et al.,15 (link) were met.
Torres V.E., Abebe K.Z., Chapman A.B., Schrier R.W., Braun W.E., Steinman T.I., Winklhofer F.T., Brosnahan G., Czarnecki P.G., Hogan M.C., Miskulin D.C., Rahbari-Oskoui F.F., Grantham J.J., Harris P.C., Flessner M.F., Moore C.G, & Perrone R.D. (2014). Angiotensin Blockade in Late Autosomal Dominant Polycystic Kidney Disease. The New England journal of medicine, 371(24), 2267-2276.
Publication 2014
Albumins Aldosterone Cardiovascular System Diagnosis Dialysis Hospitalization Kidney Failure, Acute Kidney Failure, Chronic Pain Pharmaceutical Preparations Polycystic Kidney, Autosomal Dominant Transplantation
4
Comprehensive Molecular Profiling of Astronaut Twins
The materials and methods are briefly summarized here; expanded materials and methods are included in the supplementary materials. Data were generated across human and microbial cells, including isolations of stool, saliva, skin, urine, blood, plasma, PBMCs, and immune cells that are CD4+, CD8+, and CD19+ enriched and lymphocyte-depleted (LD), from AutoMACS magnetic bead separation and validated by FACS (fig. S1). Molecular techniques included assessments of telomere length, telomerase activity, and chromosome aberration frequencies (qRT-PCR T:A, qRT-PCR TRAP, Telo-FISH, and dGH), WGBS, RNA-seq (polyA, riboRNA, and miRNA), mitochondrial quantification (qPCR and qRT-PCR), shotgun metagenome sequencing of fecal microbiome, targeted proteomics (LC-MS), untargeted proteomics (PECAN, MaxQuant for urine and SWATH-MS for plasma), targeted metabolomics (GC-MS), untargeted metabolomics (LC-MS), mitochondrial respiration (Seahorse XF), oxidative state measures (EPR), TCR and BCR (T cell and B cell receptor repertoire) profiling, 10 cognitive tests (motor praxis, visual object learning, fractal 2-back, abstract matching, line orientation, emotion recognition, matrix reasoning, digit symbol substitution, balloon analog risk, and psychomotor vigilance), vascular and ocular measures by ultrasound and optical coherence tomography, respectively, and a wide range of other biometrics (e.g., nutrition, height, and weight). Finally, a large set of biochemical profiles were measured pre-, in-, and postflight for both subjects: body mass, height, energy intake, vitamin levels (A, B6, B12, C, D, and E and 1-carbon metabolites), minerals (copper, ceruloplasmin, selenium, zinc, calcium, phosphorus, magnesium, and iodine), iron levels (ferritin, transferrin, transferrin receptors, Hgb, Hct, MCV, TIBC, and hepcidin), urine proteins (total, albumin, TTR, RBP, creatinine, metallothionein, 3-MH, nitrogen, and fibrinogen), bone markers (BSAP, PTH, OPG, RANKL, P1NP, sclerostin, and osteocalcin), collagen crosslinks (NTX, CTX, and DPD), oxidative stress and antioxidant capacity (8-OHdG, PGF2α, GPX, SOD, TAC, oxLDL, total lipid peroxides, heme, and glutathione), protein carbonyls (myeloperoxidase, lp-PLA2, neopterin, and beta-2 microglobulin), hormones and immune system markers (cytokines, testosterone, estradiol, DHEA/S, cortisol, IGF1, leptin, thyroid hormones, angiotensin, aldosterone, ANP, PRA, and insulin), and general urine chemistry (Na, K, and Cl ions; uric acid; cholesterol; triglyceride; HDL; LDL; phospholipids; renal stone risk; liver enzymes; hsCRP; NAD/P; and pH). Together, these data span 25 months for the flight subject twin (TW), who was compared with himself, either preflight, inflight, or postflight, and also with his twin control (HR) on Earth using generalized linear models (GLM), DESeq2, and fuzzy c-means clustering for longitudinal trends. All P values were corrected for multiple testing using a FDR of 0.05 or 0.01, and q values are reported in all tables.
Garrett-Bakelman F.E., Darshi M., Green S.J., Gur R.C., Lin L., Macias B.R., McKenna M.J., Meydan C., Mishra T., Nasrini J., Piening B.D., Rizzardi L.F., Sharma K., Siamwala J.H., Taylor L., Vitaterna M.H., Afkarian M., Afshinnekoo E., Ahadi S., Ambati A., Arya M., Bezdan D., Callahan C.M., Chen S., Choi A.M., Chlipala G.E., Contrepois K., Covington M., Crucian B.E., De Vivo I., Dinges D.F., Ebert D.J., Feinberg J.I., Gandara J.A., George K.A., Goutsias J., Grills G.S., Hargens A.R., Heer M., Hillary R.P., Hoofnagle A.N., Hook V.Y., Jenkinson G., Jiang P., Keshavarzian A., Laurie S.S., Lee-McMullen B., Lumpkins S.B., MacKay M., Maienschein-Cline M.G., Melnick A.M., Moore T.M., Nakahira K., Patel H.H., Pietrzyk R., Rao V., Saito R., Salins D.N., Schilling J.M., Sears D.D., Sheridan C.K., Stenger M.B., Tryggvadottir R., Urban A.E., Vaisar T., Van Espen B., Zhang J., Ziegler M.G., Zwart S.R., Charles J.B., Kundrot C.E., Scott G.B., Bailey S.M., Basner M., Feinberg A.P., Lee S.M., Mason C.E., Emmanuel M.i.g.n.o.t., Rana B.K., Smith S.M., Snyder M.P, & Turek F.W. (2019). The NASA Twins Study: A multidimensional analysis of a year-long human spaceflight. Science (New York, N.Y.), 364(6436), eaau8650.
Publication 2019
8-Hydroxy-2'-Deoxyguanosine Albumins Aldosterone Angiotensins Antioxidants BETA MICROGLOBULIN 2 BLOOD Blood Vessel Bones Calcium Carbon Cell Respiration Cells Ceruloplasmin Cholesterol Chromosome Aberrations Cognitive Testing Collagen Copper C Reactive Protein Creatinine Cytokine Dehydroepiandrosterone Sulfate Dinoprost Emotions Enzymes Estradiol Feces Ferritin Fibrinogen Fingers Fishes Gas Chromatography-Mass Spectrometry Glutathione Heme Hepcidin Homo sapiens Hormones Human Body Hydrocortisone IGF1 protein, human Insulin Iodine Ions Iron isolation Kidney Calculi Leptin Lipid Peroxides Liver Lymphocyte Magnesium Metagenome Metallothionein Microbiome MicroRNAs Minerals Mitochondria Neopterin Nitrogen Osteocalcin Oxidative Stress oxidized low density lipoprotein PAF 2-Acylhydrolase PAX5 protein, human Pecans Peroxidase Phospholipids Phosphorus Plasma Poly A procollagen Type I N-terminal peptide Proteins Receptors, Antigen, B-Cell RNA-Seq Saliva Seahorses Selenium Skin T-Lymphocyte Telomerase Telomere Testosterone Thyroid Hormones TNFSF11 protein, human Tomography, Optical Coherence Transferrin Transferrin Receptor Triglycerides Twins Ultrasonics Uric Acid Urine Vision Vitamins Wakefulness Zinc
5
Behavioral Effects of Social Isolation

Protocol full text hidden due to copyright restrictions

Open the protocol to access the free full text link

Publication 2012
Adult Aldosterone Animals Anxiety Atrium, Right Biological Assay BLOOD Brain Buffers Corticosterone Cross Reactions Diagnosis Edetic Acid Elevated Plus Maze Test Females Head Heart Human Body Immune Sera Light Locomotion Males Microtus Neurogenesis Open Field Test Plasma Plexiglas Progesterone Radioimmunoassay Radius Recognition, Psychology Sense of Smell Testosterone

Most recents protocols related to «Aldosterone»

1
Mass Spectrometry for Aldosterone Detection
Not available on PMC !

Example 8

In this example, research shows that during the mass spectrometric detection of the 5 markers, the cationic mode should be chosen to detect angiotensin I, angiotensin II, cortisol and 18-hydrocorticosterone, while the anionic mode needs to be chosen to detect aldosterone; this is because when the cationic mode is chosen, there exists a peak diagram of cortisone, an isomer of aldosterone, nearby the detection peak of aldosterone to cause larger interference, and CV % is greater than 15%; but when the anionic mode is applied for detection, the test result is more stable and accurate, and CV% is less than 8.33%.

US11860171B1. Screening kit and diagnosis system for primary aldosteronism (2024-01-02). Hangzhou Calibra Diagnostics Co., Ltd. [CN]. Inventors: Pengyun Liu [CN], Xiaofen Yuan [CN], Jinfei Ma [CN], Ziqing Kong [CN], Yikun Li [CN], Weijia Wu [CN], Huafen Liu [CN].
Full text: Click here
Patent 2024
18-Hydroxycorticosterone Aldosterone Angiotensin I Angiotensin II Cations Cortisone Hydrocortisone Isomerism Mass Spectrometry
2
Modeling Real-World RAASi Treatment Changes
In both treatment arms, all patients are initiated in the model on RAASi and are assumed to be receiving a maximum dose. Down-titration to a sub-maximal dose, or discontinuation of RAASi treatment (from any dose) may occur. RAASi use favourably impacts the progression of CKD and the incidence of MACE, hospitalisation and death (Fig. 2), with an increase in the incidence of HK; the magnitude of these impacts is further described in Supplemental Appendix A [23 (link), 36 (link)–42 (link), 46 (link)–50 ].
The proportion of patients still on RAASi at the end of the first month is specified for both arms and based on OPAL-HK trial data. For the patiromer arm, this proportion relates only to those that have achieved response, with the remaining patients assumed to be receiving RAASi therapy in line with the SoC arm. Rates of RAASi discontinuation and down-titration are taken from the OPAL-HK trial for months 2 and 3 [43 ]. From month 4 onwards, potassium level dependent RAASi discontinuation and down-titration rates were taken from Linde et al. (2019) and applied to the SoC arm [23 (link)]. Hazard ratios relating to reduced (or increased) rates of discontinuation/down-titration in those receiving patiromer in subsequent months were obtained from the OPAL-HK trial and applied to the rates from Linde et al. (2019). To reflect the impermanent nature of RAASi treatment changes in clinical practice, patients could return to optimal RAASi use independent of their potassium level with a monthly probability of 3.51% [23 (link)]. Due to a lack of relevant data, patients who down-titrated RAASi use were assumed to not return to maximum use. RAASi discontinuation and down-titration rates are summarised in Table 3.

RAASi discontinuation, down-titration and up-titration, by potassium category

Monthly probability of RAASi max discontinuation (%)Monthly probability of RAASi max down-titration (%)Monthly probability of RAASi sub-max discontinuation (%)Source
SoCPatiromerSoCPatiromerSoCPatiromer
Month 2–334.438% (6.589%)3.336% (2.421%)35.549% (6.589%)0.000% (0.000%)34.438% (6.589%)3.336% (2.421%)OPAL-HK [43 ]
Subsequent months
 K +  ≤ 52.600% (0.009%)0.181%1.800% (0.026%)1.800%2.600% (0.009%)0.181%Linde et al. (2019) [23 (link)]
 K +  > 5 to ≤ 5.53.029% (0.102%)0.211%2.617% (0.102%)2.617%3.029% (0.102%)0.211%
 K +  > 5.5 to ≤ 64.547% (0.230%)0.319%5.306% (0.230%)5.306%4.547% (0.230%)0.319%
 K +  > 610.000% (0.663%)0.721%8.900% (0.638%)8.900%10.000% (0.663%)0.721%

RAASi Renin–angiotensin–aldosterone system inhibitor, K + Potassium, SE Standard error, SoC Standard of care

Note: Complete derivation described further in Supplemental Appendix A

Ward T., Lewis R.D., Brown T., Baxter G, & de Arellano A.R. (2023). A cost-effectiveness analysis of patiromer in the UK: evaluation of hyperkalaemia treatment and lifelong RAASi maintenance in chronic kidney disease patients with and without heart failure. BMC Nephrology, 24, 47.
Full text: Click here
Publication 2023
Aldosterone Aldosterone Antagonists Angiotensins Disease Progression Myristica fragrans Patients patiromer Potassium Renin Renin Inhibitors Titrimetry VPDA protocol
3
Modeling Hyperkalaemia Event Rates and Impacts
The occurrence of HK was categorized as a serum potassium level greater than 5 mmol/l, consistent with the definitions used in the OPAL-HK trial and widely accepted in the broader HK literature [29 (link), 44 (link)]. Events were further stratified by severity (i.e., 5–5.5 mmol/l, 5.5–6 mmol/l and > 6 mmol/l). During the first three months of the modelled time horizon, incident HK events are predicted based on data from the OPAL-HK trial [29 (link), 45 (link)]. For all subsequent months, annual rates of HK were obtained from Horne et al. (2019) and applied to the SoC arm [46 (link)]. Hazard ratios relating to reduced (or increased) incidence in those receiving patiromer in subsequent years were obtained from the OPAL-HK trial and applied to the annual rates of HK obtained from Horne et al. (2019). HK event rates are summarised in Table 2. Increased potassium levels negatively impact the incidence of MACE, hospitalisation and death (Fig. 2); the magnitude of these impacts is further described in Supplemental Appendix A.

HK incidence

Time appliedPotassium levelMonthly probabilitySource
PatiromerSoC
MeanSEMeanSE
Month 1K +  > 5 to ≤ 5.521.13%3.32%21.13%3.32%OPAL-HK CSR; distributed across threshold categories in line with published data [43 , 46 (link)]
K +  > 5.5 to ≤ 61.66%1.04%1.66%1.04%
K +  > 60.38%0.50%0.38%0.50%
Month 2 & 3K +  > 5 to ≤ 5.514.00%4.68%15.00%4.81%OPAL-HK CSR [43 ]
K +  > 5.5 to ≤ 66.10%3.23%25.22%5.86%
K +  > 61.40%1.58%5.78%3.15%
Subsequent monthsaK +  > 5 to ≤ 5.50.543%0.054%1.158%0.116%Horne et al. (2019); 'OPAL-HK CSR [43 , 46 (link)]
K +  > 5.5 to ≤ 60.022%0.002%0.092%0.009%
K +  > 60.005%0.001%0.021%0.002%

HK Hyperkalaemia, RAASi Renin–angiotensin–aldosterone system inhibitor, SE Standard error, SoC Standard of care

aSoC probabilities informed by HK recurrence rates observed in Horne et al. (2019) with recurrence events distributed in line with the distribution of initial HK events across potassium categories; patiromer estimates informed by Horne et al. (2019) after application of a HR based on OPAL-HK data from months 2 and 3; SE assumed as 10% of mean

Influence of RAASi use and HK events on disease progression and events. References below each box describe the baseline probabilities/rates; references alongside arrows describe the influence of one disease component on the other, with influences applied to the baseline probabilities rates

Ward T., Lewis R.D., Brown T., Baxter G, & de Arellano A.R. (2023). A cost-effectiveness analysis of patiromer in the UK: evaluation of hyperkalaemia treatment and lifelong RAASi maintenance in chronic kidney disease patients with and without heart failure. BMC Nephrology, 24, 47.
Full text: Click here
Publication 2023
Aldosterone Aldosterone Antagonists Angiotensins Disease Progression Myristica fragrans patiromer Potassium Recurrence Renin Renin Inhibitors Serum VPDA protocol
4
Retrospective Analysis of Renal Artery Stenosis
A total of 3866 hypertensive patients with RAS referred to two tertiary referral centres in China, that is the National Center for Cardiovascular Diseases, Fuwai Hospital, Beijing, and the Department of Hypertension, Ruijin Hospital, Shanghai, between January 2000 and August 2022 were retrospectively analysed. All of the patients suffered from hypertension. Most of them were admitted for screening for the causes of hypertension and were first diagnosed as RAS at Fuwai or Ruijin Hospital. The remainder were referred to the centres for the treatment of RAS. Before being referred to the two central hospitals, the patients were diagnosed with RAS by renal computed tomography angiography (CTA) or renal artery Duplex.
Among all the RAS patients, 3209 (83.0%) were with atherosclerosis, 366 (9.5%) were with Takayasu disease and 46 (1.2%) were with other conditions. The remaining 245 (6.3%) patients met the diagnostic criteria for FMD and were subsequently included in the study.
All patients underwent a detailed investigation, including demographic characteristics (age, sex, height and ethnicity), clinical characteristics (office BP, smoking, family history of hypertension or FMD, concomitant diseases, current medications, age at diagnosis of FMD, an angiographic subtype of FMD, symptoms of FMD at diagnosis and associated atheroma lesions), biochemical sampling (plasma aldosterone, plasma renin activity), Doppler ultrasonography of carotid arteries, magnetic resonance angiography (MRA) of the intracranial artery and CTA or MRA of the abdominal and renal artery. All patients diagnosed with FMD underwent catheter-based angiography and balloon angioplasty to treat renovascular hypertension, and stent implantation should not be performed unless balloon angioplasty was failed.
The ethics committees of Fuwai Hospital, National Center for Cardiovascular Disease in Beijing and Ruijin Hospital, Shanghai Jiao Tong University School of Medicine in Shanghai approved their cohort study protocol, respectively. All participants gave written informed consent. The study was conducted in accordance with the Declaration of Helsinki.
Kang Y.Y., Chen Y., Wu Q.H., Dong H., Zou Y.B., Gao P.J., Xu J.Z., Jiang X.J, & Wang J.G. (2023). Prevalence and clinical characteristics of renovascular hypertension associated with fibromuscular dysplasia in China. Journal of Hypertension, 41(4), 638-647.
Publication 2023
Abdomen Aldosterone Angiography Angioplasty, Balloon, Coronary Arteries Atheroma Atherosclerosis Cardiovascular Diseases Catheters Computed Tomography Angiography concomitant disease Ethics Committees, Clinical Ethnicity High Blood Pressures Hypertension, Renovascular Kidney Magnetic Resonance Angiography Ovum Implantation Patients Pharmaceutical Preparations Plasma Renal Artery Renin Stents Takayasu Arteritis Ultrasonography, Carotid Arteries
5
Comprehensive Cardiovascular Assessment in Geriatric Patients
Patients’ demographic information, medical comorbidities, associated clinical data, and medications were extracted from the medical records in the geriatric cardiovascular department during the study period. Comorbidities, including diabetes mellitus, dyslipidemia, chronic kidney disease, coronary artery disease, chronic heart failure, and cerebrovascular disease, were determined on the basis of inpatient ICD‐9 diagnoses codes. Among these, chronic kidney disease was diagnosed by impaired glomerular filtration rates (< 60 ml/min/1.73 m2), or proteinuria (urinary albumin/creatinine ratio values ≥30 mg/g), persisting for more than 3 months. All participants underwent measurement of body mass index (BMI), serum urea, creatinine, uric acid, homocysteine, brain natriuretic peptide, spot urinary albumin/creatinine ratio, and brachial‐ankle pulse wave velocity (baPWV) during their hospitalization. Total 85.9% participants completed 24‐hour blood pressure monitoring and had effective data. Estimated glomerular filtration rates were estimated from serum creatinine levels and the Chronic Kidney Disease Epidemiology Collaboration equation.9 The baPWV was automatically measured by two trained researchers using form PWV/ABI instruments (form PWV/ABI, BP‐203RPE III; Omron‐Colin, Japan). Further screening for secondary hypertension, including serum potassium, renin, aldosterone, plasma metanephrine levels, thyroid function tests, 24‐h urinary potassium, renal artery ultrasound or computed tomography angiography, adrenal computed tomography scan or magnetic resonance imaging, and polysomnography, and so on, which was guided by history, clinical examination, and baseline laboratory data, was conducted in patients who were diagnosed as RHTN according to the latest guidelines.10 The diagnosis of secondary hypertension, including chronic kidney disease, obstructive sleep apnea, primary aldosteronism, renovascular disease were conducted according to the associated guidelines.11, 12, 13, 14For measurements of systemic hemodynamics, a CNAP™ monitor (CN Systems Medizintechnik AG, Graz, Austria), which is a continuous noninvasive arterial pressure measurement device, was used. The CNAP™ monitor has been validated for arterial BP, cardiac output, and other hemodynamics.15 Hemodynamic measurements were performed by two fixed trained researchers. An appropriately sized finger cuff of the CNAP™ monitor was affixed to each participant's finger, after a 5‐min supine resting period, and the measurement hand was placed on side of the body. The beat‐to‐beat measurements of systolic BP, diastolic BP, heart rate, cardiac output, and systemic vascular resistance of all participants were performed in the supine position.
Geng H., Chen X., Liang W, & Liu M. (2023). Associated factors and hemodynamic characteristics of resistant hypertension in the elderly. The Journal of Clinical Hypertension, 25(3), 259-265.
Publication 2023
Albumins Aldosterone Ankle Arteries Blood Pressure Cardiac Output Cardiovascular System Cerebrovascular Disorders Chronic Kidney Diseases Computed Tomography Angiography Conn Syndrome Coronary Artery Disease Creatinine Diabetes Mellitus Diagnosis Dyslipidemias Fingers Glomerular Filtration Rate Heart Failure Hemodynamics High Blood Pressures Homocysteine Hospitalization Human Body Inpatient Measure, Body Metanephrine Nesiritide Patients Pharmaceutical Preparations Physical Examination Plasma Polysomnography Potassium Pressure, Diastolic Radionuclide Imaging Rate, Heart Renal Artery Renin Serum Sleep Apnea, Obstructive Sphygmomanometers Systolic Pressure Thyroid Function Tests Total Peripheral Resistance Ultrasonography Urea Uric Acid Urine X-Ray Computed Tomography

Top products related to «Aldosterone»

1
Aldosterone by Merck Group
Sourced in United States, United Kingdom, France, Japan, Switzerland
Aldosterone is a laboratory equipment product designed for the measurement and analysis of aldosterone, a hormone produced by the adrenal glands. The core function of this product is to provide accurate and reliable quantification of aldosterone levels in biological samples, such as blood or urine. This information can be used by healthcare professionals to assess adrenal gland function and investigate conditions related to aldosterone imbalance.
2
Corticosterone by Merck Group
Sourced in United States, China, United Kingdom, Germany, Italy, France, Sao Tome and Principe
Corticosterone is a laboratory reagent used in scientific research. It is a naturally occurring steroid hormone produced by the adrenal glands in various species. Corticosterone plays a role in the regulation of metabolism, immune function, and stress response. As a research tool, it is often utilized in studies involving endocrinology, neuroscience, and pharmacology.
3
Spironolactone by Merck Group
Sourced in United States, Germany, France, United Kingdom
Spironolactone is a potassium-sparing diuretic medication manufactured by Merck Group. It is a synthetic steroid compound that inhibits the actions of aldosterone, a hormone involved in the regulation of blood pressure and fluid balance. Spironolactone is used to treat conditions such as heart failure, high blood pressure, and fluid retention.
4
Dexamethasone (dex) by Merck Group
Sourced in United States, Germany, United Kingdom, China, Japan, Italy, Sao Tome and Principe, Macao, France, Australia, Switzerland, Canada, Denmark, Spain, Israel, Belgium, Ireland, Morocco, Brazil, Netherlands, Sweden, New Zealand, Austria, Czechia, Senegal, Poland, India, Portugal
Dexamethasone is a synthetic glucocorticoid medication used in a variety of medical applications. It is primarily used as an anti-inflammatory and immunosuppressant agent.
5
Spac s aldosterone kit by Fujirebio
Sourced in Japan
The SPAC-S Aldosterone Kit is a laboratory equipment product designed for the quantitative determination of aldosterone levels in human serum or plasma samples. The kit utilizes a solid-phase radioimmunoassay (RIA) technique.
6
Fetal bovine serum (fbs) by Thermo Fisher Scientific
Sourced in United States, China, United Kingdom, Germany, Australia, Japan, Canada, Italy, France, Switzerland, New Zealand, Brazil, Belgium, India, Spain, Israel, Austria, Poland, Ireland, Sweden, Macao, Netherlands, Denmark, Cameroon, Singapore, Portugal, Argentina, Holy See (Vatican City State), Morocco, Uruguay, Mexico, Thailand, Sao Tome and Principe, Hungary, Panama, Hong Kong, Norway, United Arab Emirates, Czechia, Russian Federation, Chile, Moldova, Republic of, Gabon, Palestine, State of, Saudi Arabia, Senegal
Fetal Bovine Serum (FBS) is a cell culture supplement derived from the blood of bovine fetuses. FBS provides a source of proteins, growth factors, and other components that support the growth and maintenance of various cell types in in vitro cell culture applications.
7
D aldosterone by Merck Group
Sourced in United States
D-aldosterone is a laboratory product used for research purposes. It is a steroid hormone that plays a role in the regulation of electrolyte and fluid balance in the body. The core function of D-aldosterone is to maintain sodium and potassium homeostasis. This product is intended for use in scientific research and analysis, and its specific applications may vary depending on the research objectives.
8
Adi 900 173 by Enzo Life Sciences
Sourced in United States
The ADI-900-173 is a laboratory instrument designed for use in scientific research and analysis. It serves as a core piece of equipment for researchers and scientists. The device specifications and technical details are available upon request.
9
Aldosterone elisa kit by Enzo Life Sciences
Sourced in United States
The Aldosterone ELISA Kit is a quantitative in vitro diagnostic assay designed to measure the levels of aldosterone, a steroid hormone, in human serum or plasma samples. The kit utilizes the enzyme-linked immunosorbent assay (ELISA) technique to determine the aldosterone concentration.
10
Coat a count aldosterone by Siemens
Sourced in Germany, United States
Coat-a-Count Aldosterone is a laboratory equipment product used for the quantitative measurement of aldosterone levels in human serum or plasma samples. It is a radioimmunoassay-based test that provides accurate and reliable results for diagnostic purposes.

More about "Aldosterone"